Diagnostics

Assays For Five Life-Threatening Cancers Derived From Gold Standard Antibodies

Published in Cancer Weekly, January 29th, 2002

Fujirebio Diagnostics, Inc. (FDI), formerly Centocor Diagnostics, a manufacturer of diagnostic assays for early detection of cancer recurrence, announced that it would begin marketing a new line of six enzyme immunoassays (EIAs) in microtiter format.

The innovative new EIAs will be based on the same gold standard antibodies utilized in the Fujirebio Diagnostics Radioimmunoassays (RIA). The assays will be available in Southeast Asia in Q1 2002 and later launched in Latin America, the Middle East, and Eastern Europe. The assays were codeveloped with Trinity Biotech , an international medical diagnostics company.

The new EIAs will target ovarian...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry